Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of February 2–8, 2026 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Psyence Biomedical Ltd. (PBM): Psyence Biomedical's 1-for-6.25 share consolidation takes effect
Psyence Biomedical implemented a previously delayed 1-for-6.25 reverse share consolidation, a step aimed at supporting its Nasdaq listing compliance and share price. The palliative-care-focused psilocybin developer continued advancing its NPX-5 program for adjustment disorder in cancer patients. Reverse splits were a recurring theme among small-cap psychedelic names navigating exchange minimum-price rules in early 2026.
Source: psyencebiomed.com
Compass Pathways plc (CMPS): Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
STAT reported that senior HHS and White House officials blocked FDA Commissioner Marty Makary's plan to grant COMP360 psilocybin a Commissioner's National Priority Voucher, which promised a compressed 1-2 month review; of ten proposed drugs, psilocybin was the only one vetoed. COMP360 retained its Breakthrough Therapy Designation and rolling-review eligibility, so the core approval pathway was intact, but the episode signaled political sensitivity around psychedelics. The decision was later reversed in April 2026 when the FDA did issue Compass a priority voucher.
Source: statnews.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.